Synthekine Collaborates With Sanofi To Develop Selective IL-10 Agonists For Treatment Of Inflammatory Diseases; Synthekine To Receive $40M Payment; Eligible For Additional Payments And Royalties
Portfolio Pulse from Benzinga Newsdesk
Synthekine has entered into a collaboration with Sanofi to develop selective IL-10 agonists for the treatment of inflammatory diseases. Synthekine will receive an upfront payment of $40 million and is eligible for additional milestone payments and tiered royalties on net sales.
January 29, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi has partnered with Synthekine to develop IL-10 agonists for inflammatory diseases, providing Synthekine with a $40 million upfront payment and potential future financial benefits.
The collaboration with Synthekine could potentially lead to the development of a new treatment for inflammatory diseases, which is a significant market. The upfront payment of $40 million, along with the potential for milestone payments and royalties, indicates a strong commitment to the project and could have a positive impact on Sanofi's stock in the short term as it reflects the company's proactive approach in expanding its pipeline.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80